

Biota Holdings Limited

ACN 006 479 081

10/585 Blackburn Road
Notting Hill VIC 3168
Australia**T** +61 3 9915 3700**F** +61 3 9915 3702**E** info@biota.com.au**W** www.biota.com.au

For Immediate Release

Melbourne, Australia — 29 October 2009

Relenza Q1 Royalty

Biota Holdings Limited (ASX:BTA) today announced that it had received written notification from GlaxoSmithKline (GSK) that Relenza sales were \$331 million and indicative royalties were \$24.1 million, for the three months ended 30 September 2009. GSK advised that the figures were calculated on an Australian dollar exchange rate of 1.8225 A\$ to the UK pound.

Actual payment will be calculated on the exchange rate of 30 April 2010.

About Biota

Biota is a leading anti-infective drug development company based in Melbourne Australia, with key expertise in respiratory diseases, particularly influenza. Biota developed the first-in-class neuraminidase inhibitor, zanamivir, subsequently marketed by GlaxoSmithKline as Relenza. Biota research breakthroughs have included novel nucleoside analogues designed to treat hepatitis C virus (HCV) infections, licensed to Boehringer Ingelheim, and a series of candidate drugs aimed at treatment of respiratory syncytial virus (RSV) disease. Biota has clinical trials underway with its lead compound for human rhinovirus (HRV) infection in patients with compromised respiration or immune systems.

In addition, Biota has a key partnership with Daiichi Sankyo for the development of second generation influenza anti-virals.

Relenza™ is a registered trademark of the GlaxoSmithKline group of companies.

*Further information available at www.biota.com.au

Investor / Analyst Enquiries
Biota Holdings LimitedPeter Cook
T: +61 3 9915 3720
Damian Lismore
T: +61 3 9915 3721**Media Enquiries**Jo Lynch
Hinton & Associates
T: +61 3 9600 1979
M: +61 411 208 101

For personal use only